Your session is about to expire
← Back to Search
Riociguat for Sarcoidosis (RioSAPH Trial)
Phase 4
Waitlist Available
Led By Robert P Baughman, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights
RioSAPH Trial Summary
Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension
Eligible Conditions
- Sarcoidosis
RioSAPH Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time until clinical worsening
Secondary outcome measures
Pulmonary function
Quality of life
Safety: adverse events
+1 moreRioSAPH Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: RiociguatActive Control1 Intervention
Active drug
Group II: PlaceboPlacebo Group1 Intervention
placebo
Find a Location
Who is running the clinical trial?
University of CincinnatiLead Sponsor
428 Previous Clinical Trials
634,326 Total Patients Enrolled
14 Trials studying Sarcoidosis
3,712 Patients Enrolled for Sarcoidosis
Robert P Baughman, MDPrincipal InvestigatorUniversity of Cincinnati
10 Previous Clinical Trials
2,530 Total Patients Enrolled
9 Trials studying Sarcoidosis
2,515 Patients Enrolled for Sarcoidosis
Steve Nathan, MDPrincipal InvestigatorInova Fairfax Hospital
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger